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Clinical research is often delayed by the lack of data and the need for ethical approval. We suggest that this need could
be initially satisﬁed by synthetic data that has the same characteristics as those from patient records. The generation of
this data requires some domain knowledge to ensure appropriate data management. As an exemplar of this concept we
generate patients presenting with undifferentiated chest pain at Emergency Department (ED). Their diagnosis uses
biochemical markers indicative of myocardial cell damage. Efﬁcient diagnosis is paramount and a number of different
competing protocols have been advocated. Analysis of resulting data shows that while the measurement of cardiac
markers may not register above a cut-off value that the time differentiated rule-out protocols are valuable indicators of
disease. We therefore demonstrate both concept and value of the use of synthetic data that would have taken years to
gather and not have been reproducible or repeatable.
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Introduction
Clinical data is a valuable commodity and difﬁcult to obtain.
Often the reason being espoused for the non-proliferation of
data are the ethical issues associated with patient informa-
tion. The incentive to share the object of their research
should be good science. Good science should be reprodu-
cible and veriﬁable but how can this be if the original data is
not made available to others who may wish to understand
how and from where the summary statistics were derived.
The NHS (www.connectingforhealth.nhs.uk/systemsandser
vices/infogov) and the Ministry of Justice have deliberated
on these issues and have recommended in the Data Sharing
Review (www.justice.gov.uk/docs/data-sharing-review-report.
pdf) that there is a need to develop mechanisms whereby
research and statistical analysis for public beneﬁt can be
carried out while still safeguarding the privacy of individuals.
The aim of this paper is to explore a technique of using
machine generated patient data for the investigation of
clinical procedures. Our eventual aim is to be able to
produce synthetic patient data sets with more variables,
which have the same statistical properties and interdepen-
dencies as the original sample data set. The essential feature
of these data is that they do not relate to any individual
patient (unlike re-sampling methods) but are entirely artiﬁcial.
As such, conﬁdentiality and ethical issues will not apply.
We are not advocating that simulations fed with synthetic
data should form the basis for policy changes in patient care.
Rather, that those simulations can be used to explore
procedures; the economic value of novel medical devices can
be evaluated and that researchers can hone their hypotheses
in a virtual world before the clinical trials are conducted live.
Simulation is increasingly being used to study patient
pathways (Lattimer et al, 2004) and to study diagnostic
practice using a manikin with appropriately generated
symptoms (Brendan et al, 2002; DeVita et al, 2005). On a
systems scale, the East of England SHA in collaboration
with Simul8 corporation have created a Scenario Gen-
erator—a simulation tool that will facilitate investigation
into the logistics of patient access, stafﬁng and costing
(www.healthcareworkforce.nhs.uk/workforceplannermenus/
index.php?option¼com_docman&task¼doc_view&gid¼3).
Only recently has synthetic patient data been used to feed
such simulations (Dutta et al, 2005; McCabe et al, 2008). We
believe that this is one possible way to assist the design of
experiments and clarify the process that will lead to
obtaining ethical approval for clinical trials. The freedom
from the ethics restrictions imposed will, at least in part,
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remove the disincentive to share data and thereby encourage
knowledge generation through openness of research ﬁndings.
This study presents an exemplar case for patients
presenting at ED with chest pain, a scenario that is of great
clinical and economic importance to the NHS. An estimated
500 000 patients present to ED with chest pain each year,
which is 25% of all admissions and at a cost of some
d15 billion (Fox, 2005; Rajappan et al, 2005). However,
a general analysis has shown that some two-thirds of
presenting patients have non-cardiac chest pain. Of those
that are cardiac related, 40% of these patients will have low
risk of Acute Myocardial Infarction (AMI) (Turab et al,
2006). Although it is clear that misdiagnosis incurs
additional cost and jeopardises patient wellbeing, these
patients may have to be admitted due to insufﬁcient clinical
evidence to allow their safe discharge. This contributes
a signiﬁcant and unnecessary cost burden to the NHS.
Furthermore, Turab et al (2006) reported that between 2 and
10% of the presenting patient group are inappropriately
discharged with undiagnosed AMI.
There is a need for an improved rapid rule-out diagnostic
test to differentiate these patients and contribute to reducing
hospital admission costs. Benger et al (2002) cites that in the
United Kingdom 300000 people suffer an acute heart attack
each year, of whom 50% die. Of those, about one-third of all
deaths occur within the ﬁrst hour (NICE, 2002) giving a
narrow time window for diagnosis and intervention. Any
time delay taken to initiate treatment is therefore signiﬁcant.
A preferred treatment of AMI is with thrombolytic drugs
administered intravenously. This therapy operates by
dissolving the offending clot formation in the coronary
artery; however its effectiveness is greatest when it is
administered early (Carley, 2002; Heath et al, 2003).
However, there are risks associated with thrombolytic
therapy and it must only be administered to those with
conﬁrmed AMI and only then with caution. Accurate and
rapid diagnosis is therefore highly desirable. Efﬁcient
diagnosis of AMI is paramount and the most effective
identiﬁers of myocardial cell damage are the presence of
the cardiac markers myoglobin, troponin I and CK-MB in
the blood. These proteins that originate within the cells of
the heart can be measured by a Point-of-Care device (PoC)
and if found to be elevated are strong evidence of cellular
damage. The testing for the cardiac marker troponin has
become a gold standard of AMI diagnosis rather than just
another indicator.
The essential advantages of identifying the elevation of
cardiac markers with PoC is the rapidity of the test
turnaround time and the resultant seamless and, consistent
approach to coronary care. The turnaround time is typically
between 12 and 20min for PoC as compared with about an
hour for a pathology laboratory, depending on proximity
and staff shift times. For cardiac patients this time difference
could be vital. It will allow ED staff to accurately identify
those patients that can start treatment immediately, thus
increasing their chances of survival.
A further signiﬁcance of this rapid turnaround time is that
it provides for the possibility of alternative protocol path-
ways that otherwise would not be practical. A number of
different rule-out protocols have been advocated for the
diagnosis of patients using PoC (McCord et al, 2001;
Ng et al, 2001) in which the time differential of cardiac
marker levels is recorded and if it varies for any of the
cardiac markers by more than 25%, this can be deemed as
evidence of ischemic processes. By rule-out is meant to
establish beyond reasonable doubt that the patient is not
AMI. The relative beneﬁts of these rule-out protocols have
been much debated (Goodacre et al, 2004, 2005; Collinson
et al, 2006; Body, 2008). Consequently, the protocols present
a paradigm shift from the early diagnosis of AMI. This
study seeks to obtain data that can quantify the clinical
beneﬁt of PoC in cardiac screening. In this study we assess
the value of these alternative PoC protocols using synthetic
patient data generated with the same statistical characteri-
stics as that of the sample data set.
The results of the simulation study shows that while the
measurement of cardiac markers may not register above
a cut-off value before 6 h after onset, that the rule-out
protocols outlined by Ng et al (2001) and McCord et al
(2001) could be valuable indicators of cardiac necrosis. The
length of the time differential is important suggesting
a diminishing return of sensitivity with delay. Experimenta-
tion shows that the sensitivity of the rule-out test is 94.9%
at 90min, 98.4% at 120min and 99.0% at 180min.
Thus this paper demonstrates the value of synthetic data.
Although it would have taken years to gather such data, it
would not have been reproducible or repeatable. Such data
would permit free exchange of information without the need
for ethical approval. It is anticipated that the future will see
synthetic data generation that handles more variables
retaining interdependencies and passing the ‘Turing test’
(http://en.wikipedia.org/wiki/Turing_test) for clinical data.
Materials and method
The seed data for this study comprise the records of
137 patients that presented with chest pain at the ED at
the Royal Victoria Hospital, Belfast between October 2007
and January 2008. The data recorded includes aspects of
their medical history; arrival times; details of the patient
diagnostic pathway and results of those tests; their
preliminary diagnosis; ED departure time; hospital admis-
sion or otherwise and if they were admitted, the date of
release from hospital and discharge diagnosis. Cardiac
markers are tested using a Biosite Triage PoC device. These
data are supplemented with summary statistics from a
related study of 546 patients at the same hospital between
2004 and 2005 (Hamilton et al, 2008). These data can be
164 Journal of Simulation Vol. 3, No. 3
assumed to have the same demographic characteristics as
our data taken at a later date. Information is also
sequestered from other literature (Goodacre et al, 2007).
The aim is to assess the likely beneﬁts of different AMI
rule-out protocols that have been suggested in the literature
using simulated patients. The patient generator tool uses
Weibull distributions for troponin levels in the blood for
diseased and non-diseased patients. The parameters gener-
ated for each patient are a subset of those that would
generally be taken at triage on entry to ED. The model
assumes a likelihood of a patient being AMI as the
prevalence in the population of 10.8% (Hamilton et al,
2008). Given that the patient is positive for AMI, the model
generates a severity index from a parametric distribution of
troponin values from our diseased population. If the patient
is not diseased, the troponin level is similarly selected from
the distribution for healthy patients.
The temporal proﬁles of these cardiac marker are taken
from an internally published presentation (Adams, 2008).
The cardiac markers are released from heart muscle cells as
they die. There are a number of such proﬁles published
showing the rise of cardiac markers and this representation
has a good conformity with the authors published works. As
can be seen from Figure 2 the time proﬁle of each marker
has a characteristic delay before it is detectable and therefore
would not give a positive result with the PoC device until
levels increase to the threshold for that device. For example,
troponin levels are raised within 4–6 h after onset of chest
pain, peak at 12–20h and remain elevated for 3–10 days. The
elevation of the cardiac markers will depend on the severity
of the disease and each one, as indicated in Figure 2, will
remain proportionate to other markers for a given severity
and time from onset. It can be seen from this proﬁle that it is
therefore important to know when the onset of AMI
occurred. This value has been recorded for the patient data
record and the model notes the delay after the time of onset
that the blood sample is taken for the cardiac marker.
A Judicious use of PoC
As the speed of diagnosis of chest pain is critical to prevent
further cardiac damage, the objective is to accurately and
efﬁciently assess the likelihood of AMI. The cardiac markers
however, may not be elevated and will not reach a cut-off
value for at least 3 h after onset. Until that time it is not
appropriate to test for cardiac markers. Traditionally the
cut-off value for troponin at which a patient is considered to
be diseased is arbitrarily set at the 99th percentile of the level
of a healthy population (Apple et al, 2005). Although this
deﬁnition is widely adopted, the critical value may vary with
demographics (Apple et al, 2003).
A number of authors have experimented with variations
of an AMI rule-out protocol (McCord et al, 2001; Ng et al,
2001; Dunn et al, 2006). They argue it has many advantages
over the traditional blood test for cardiac markers that use a
predeﬁned critical cut-off value. The proposed rule-out
protocols are less concerned with the time of onset or critical
values. Using PoC to assess the three cardiac markers
(myoglobin, troponin I and CK-MB) on arrival an initial
base value is obtained. If it is within the normal range, then a
further blood test is taken at a later time, for example
120min. If any of the cardiac markers are elevated from
the base value by greater than 25%, even if those values are
within their normal range, then this is evidence that cardiac
cell damage is in progress and the patient is admitted. The
rule-out along with other diagnostic tests allows hospitals
some conﬁdence in discharging patients as cited by Dunn
et al (2006) who reported some 40% reduction in admissions
with this protocol.
The model
The aim of this exemplar model is to compare the
effectiveness of a current chest pain protocol with what
has become know as the 90min rule-out (Ng et al, 2001) the
120min rule-out (Dunn et al, 2006) and to explore a 180min
rule-out. The characteristics of the synthetic data are
designed to conform to those of the data sample that has
been collected from hospital records of the Royal Victoria
Hospital (RVH). The data generation draws from empirical
knowledge obtained from the live data set and reasoned
principles of the parametric properties of those data guided
by domain knowledge. The data is also augmented from
similar studies and in particular summary data from
previous work by Hamilton et al (2008). The data related
to the same demographic population of patients at RVH
entering ED with chest pain.
From the above research we may take the population
prevalence of the cardiac disease (0.108), the sensitivity
(0.789) and the speciﬁcity (0.967) for Troponin T. Using
Equation (1) and (2), this information permits the construc-
tion of the matrix in Table 1 showing the probabilities of
a correct diagnosis of a patient’s condition given a positive
or negative test result for troponin.
Sensitivity ¼ Number of TruePositives
Number of TruePositives
þNumber of FalseNegatives
ð1Þ
Selectivity ¼ Number of TrueNegatives
Number of TrueNegatives
þNumber of FalsePositives
ð2Þ
Using the PoC device for the detection of troponin, the
cut-off of value is 0.09ng/ml above which the patient is
deemed to be AMI is which corresponds to the 99th
percentile of the healthy population distribution (Apple et al,
2003). It is also know that the healthy population typically
has a troponin proﬁle described in Figure 1. The shape of the
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distribution to the left of the cut-off point is not of great
importance here, but its similarity to a Weibull distribution
is noted. This distribution is generally used in reliability
analysis and time-to-failure proﬁles in a variety of contexts.
As cardiac marker enzymes are an indicator of cardiac cell
death (component failure), which must occur occasionally
even in a healthy person and that blood troponin levels are
a direct consequence of those cell deaths, then it would seem
appropriate to use this distribution to describe the troponin
occurrence in both the healthy and the diseased population.
Although the distribution of troponin levels from the
available records of the diseased population bears a reason-
able likeness to the Weibull distribution, it is not so easily
parameterised with such low recorded values. This distribu-
tion has a correction factor added so as to be calibrated
against the reported sensitivity found using the PoC device
that was used at the optimum time for troponin detection.
The ED staff intent was to take a blood test some 6h after
onset though the exact timing cannot be certain.
The simulation interprets this distribution as an index of
the likely severity of AMI and is used to attenuate the
amplitude of the cardiac marker values found from the
cardiac marker proﬁles given in Figure 2. The matrix
(Table 1) shows that the diseased population has a
probability of 0.023 of being mistakenly identiﬁed as healthy
(false positive). That is 2.3% of the diseased population will
give values below that of the cut-off value. The data from the
hospital records shows a diseased troponin distribution
similar to that in Figure 1.
Each of the cardiac markers has a time related proﬁle with
hours¼ 0 at the time of onset of the chest pain (Figure 2).
The ﬁrst marker to become evident is myoglobin after
approximately 2 h, likewise CK-MB after 4–6h and troponin
I after 4–8h, each reaching a peak before slowly declining.
Figure 2 also shows the cut-off values for each of the cardiac
markers.
Patient records show the time of onset of chest pain
and the time of arrival. These values are plotted in Figure 3
and show some anomalies. From these data it appears that
patients who experience symptom onset between 18:00 and
21:00 will, on average, wait more than twice as long before
attending ED than those patients whose onset is between
22:00 and 13:00. This bimodal distribution of delays is
described with two Poisson distributions also shown in
Figure 3. To obtain a probability density function, the two
distributions are summed and the result normalised. The
rationale for this is that this distribution is often used
to describe random queuing events. It would be tempting
to surmise that those patients with the most acute symptoms
of AMI would attend ED without delay. Although a severe
Table 1 Confusion matrix derived from Equations 1 and 2
Test Diseased pop. Healthy pop. Total
þ ve 0.085 0.029 0.114
ve 0.023 0.863 0.886
Total 0.108 0.892 1.00
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Figure 1 Probability distribution of troponin I in healthy and diseased population.
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attack should elicit an immediate transfer to hospital, there
is no evidence for this in the data. One relatively severe case
waited 3 days before attending ED. The proﬁle of the
diurnal cycle of ED attendance on the other hand is a well-
deﬁned bell curve with a mean of 15:00. It would appear
therefore that people wait for a convenient time to attend
ED. As a note of caution however, the delay between
onset and arrival at ED is not measured by hospital staff; it
is information volunteered by the patient. Although it is
accepted that this time cannot therefore be veriﬁed, it is the
only data that the hospital have to assess the progress of the
AMI and is therefore used in this model.
The simulation involves the generation of a series of
patient instances that have a time delay since chest pain
onset taken as a random variable from the distribution
described in Figure 3. This time value is used as an index to
obtain the cardiac enzyme proﬁle from Figure 2 for that
time. A further random variable is used to select a severity
for the AMI from the diseased population distribution in
Figure 1. This value is used to attenuate the values of the
cardiac enzymes established above. With this method it is
possible to create a realistic stochastic representation of the
cardiac marker values for each patient with respect to the
delay since onset. The diagnostic model receives this data as
input. The simulation records the troponin level at the time
of arrival and at 90, 120 and 180min after arrival. If any of
the readings are above the critical threshold (see Figure 2)
for any of the markers or the subsequent reading shows
more than a 25% increase in troponin I, CK-MB or
myoglobin than the ﬁrst reading, then the patient is regarded
as having AMI.
For the AMI positive patients, one thousand patients
were generated for each of the 90min rule-out, the 120min
rule-out and the 180min rule-out protocols. The possible
outcomes for each patient are that they were diagnosed at
the ﬁrst blood test or at the second blood test or, if both were
negative; then the results of the two tests are compared to see
if any of the cardiac markers in the second test are more
than 25% more or less than the ﬁrst test. It is noted that
because of the excessive delay of ED presentation after
the chest pain onset, the cardiac markers may be on the
decline. Regardless, the 25% change is recorded as an AMI
indicator. The experiment is repeated 100 times.
Results and discussion
The model creates a series of patients with a 10.8%
probability of AMI. For those deemed to have AMI, the
delay since the onset is assigned to the patient from the
distribution in Figure 3. That value indexes the distributions
in Figure 2 to give the level of cardiac markers. The severity
of disease is chosen from the disease proﬁle in Figure 1.
Those patients that are healthy are taken to have a troponin I
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level from the healthy proﬁle in Figure 1 and as such, the
probability of the patients having a troponin level higher
than the cut-off value is 1%, this being the prerequisite for
this distribution. It is not known from the literature how the
troponin level of a healthy person varies with the period of
the rule-out interval of between 90 and 180min. If the
patient is healthy, there is little reason to believe that it
would change at all though there are random errors within
the PoC device (Purchasing and Supply Agency, 2006) that
may give some anomalous readings.
The virtual experiment involving 1000 patients was
repeated 100 times for each of the three rule-out protocols.
Table 2 gives the percentages that would have been
accurately diagnosed by the ﬁrst test at presentation. Failing
diagnosis at presentation, the percentage that would be
diagnosed at the second test at the rule-out interval is given.
The third column shows the percentage that would be
diagnosed by the comparison of the ﬁrst test and the second,
given that neither individually had diagnosed AMI. The
fourth column shows the percentage that is misdiagnosed by
these protocols.
The most critical value is the false negative diagnosis for
each of protocols. The 90min rule-out has a sensitivity of
94.9% that may be compared with Ng et al (2001) and
McCord et al (2001) who found sensitivity of 100% and
96.9%, respectively, for their 90min rule-out. The 180min
rule-out has 99% sensitivity. Some 70% of those presenting
are dependent on the second test for diagnosis. This of
course requires a delay of a critical 3 h before the second test
result becomes known. Although it is critical that delay is
kept to a minimum, the increased accuracy of the test may
be important, though of diminishing return value. That is,
that the increase in sensitivity may be worth waiting 120min
for but not 180min.
It is interesting to review the proﬁle of the patients that
would be diagnosed at each stage in Figure 4. Those dia-
gnosed by the ﬁrst or second test are typically in their 10–15h
since onset of chest pain which is slightly earlier for those
diagnosed by the second test only. Those for whom the
diagnosis is a false negative are on average tested 18h after
onset and typically only have mild AMI. For these patients,
the delay of further diagnosis may not be a life-threatening
situation. It can be seen that the rule-out comparisons are
a most powerful diagnostic test especially where the ﬁrst two
tests alone provided insufﬁcient evidence of AMI. The proﬁle
of the patients that were diagnosed by the rule-out were on
average tested 2.7 h since chest pain onset at presentation,
much earlier than is generally recommended for a ﬁrst test.
Given the urgency for early diagnosis and treatment with
thrombolytic drugs, the rule-out protocols would seem to be
a valuable course of action. There is considerable difference
in comparison with non-rule-out protocols. Hamilton et al
(2008) records a sensitivity of 78.9% with troponin and
Goodacre et al (2005) records a sensitivity with troponin of
83.3% at a 0.1 ng/ml cut-off. Both these diagnostic tests
would have conducted over 6h after onset.
Table 2 Showing the percentages diagnosed as AMI at the ﬁrst test, second test or by 25% elevation of cardiac markers at second
test. Also shown, those patients for whom AMI was not diagnosed
Test 1 (presentation) Test 2 (rule-out interval) 25% elevation False negative
Minutes Mean (%) Sd (%) Mean (%) Sd (%) Mean (%) Sd (%) Mean (%) Sd (%)
90 26.2 1.5 3.0 0.5 65.8 1.5 5.1 0.7
120 26.4 1.3 5.6 0.7 66.5 1.4 1.6 0.4
180 26.1 1.2 8.4 0.9 64.5 1.4 1.0 0.3
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Figure 4 Delay in diagnosis of AMI using the ﬁrst, second and 120min rule-out protocols. (histogram cropped to emphasise lower
counts—thumbnail to show scale)
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The evidence from the model suggests that rule-out
protocol is a useful tool to have in the toolbox. It is not
the only tool however, and it of course has to be used
in conjunction with ECG, TIMI scores and with the wisdom
and experience accrued by healthcare professionals working
many years in cardiac care. It must be pointed out that,
however valuable the rapid rule-out protocol is, cardiac
markers will not identify disease where there is insigniﬁcant
myocardial necrosis, such as may be found with unstable
angina. Similarly, myoglobin is not speciﬁc to cardiac
necrosis and may not indicate AMI if it is the only cardiac
marker present. Studies by the International Liaison
Committee on Resuscitation (2005) suggest that rapid rule-
out protocols as suggested above should not be recommend
before 6 h since onset. This would seem to be missing the
point of rapid rule-out and to negate its key strength.
Conclusion
The aim of this paper was to demonstrate that while there
may be some apprehension in the use of synthetic data, there
is signiﬁcant value in the practice. Although this exemplar
is little more than a proof of concept, it can clearly be seen
that the quality of data can be improved with time
and experience until it will eventually pass the ‘Turing Test’
of medical data. Given sufﬁcient true information, methods
of principal components or Bayesian belief networks can
be used to reproduce probabilistic interdependencies thus
allowing diagnostic inference to be learned from the
synthetic data.
In a hospital environment the data generated in this
analysis would have taken years to accumulate and multiple
repetitions would just not have been possible. Using this
data to research the use of cardiac marker rule-out protocols
permits the exploration of these protocols without endanger-
ing lives. It allows one to examine which parameters the
model is most sensitive to highlight the information that
needs to be gathered and to design better trials to test
hypothesis. It also permits the open sharing of data between
co-workers so that the experiment will be reproducible and
open to scrutiny.
There will always be dangers involved in the use of
synthetic data. Where it is seeded from sample live data there
is the risk of bias. If the original sample were biased, maybe
as a result of being taken from a small sample, the generated
data will also reﬂect that bias. Although this is true, the same
problem could as easily arise if real data were used in a pilot
study. However, there is here an advantage of synthetic data.
Given that such bias will in all probability arise inadvertently
anyway, the synthetic data has the ability to test the
sensitivity to such a bias by actively loading the data. As
mentioned above, the data is not intended to change clinical
practice, but to provide a tool to explore issues in clinical
practice and design better experiments to verify new
procedures. In the words of Alfred North Whitehead, ‘Seek
simplicity, and distrust it’.
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